Pre-launch biotech with FDA PDUFA on Nov 22, 2026 for MOLBREEVI (molgramostim), a first-in-class inhaled therapy for autoimmune pulmonary alveolar proteinosis (aPAP), a rare orphan lung disease with no approved US therapy. Phase 3 IMPALA-2 met primary endpoint; FDA review extension in Aug 2026 was procedural (CMC amendment, not safety/efficacy). Priority Review and no AdCom planned. Dislocation thesis: market pricing in excessive binary risk despite de-risked clinical and manufacturing profile.
rNPV probability-weighted model. Approval probability 75% supported by: (i) Phase 3 IMPALA-2 primary endpoint met with statistical significance in exercise capacity and gas transfer; (ii) FDA Day 74 letter confirmed no AdCom needed; (iii) FDA extension (Aug 2026) was procedural (major amendment classification), with no safety/efficacy/manufacturing concerns cited; (iv) orphan designation + fast-track + priority review + Fujifilm as new BLA manufacturer. Peak sales $400M US based on ~8,300 US prevalent patients × ~25% peak penetration × ~$190K/pt/yr orphan pricing. Implied multiple 4.9x EV/peak sales (approval scenario, un-weighted) is in line with peer median; the asymmetry is driven by the 75/25 probability weighting between approval and rejection scenarios, not multiple compression. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| US aPAP commercial NPV (approval scenario) | $400M peak sales × 4.9x EV/peak sales × 75% prob = $1,476M / 254M shares | +5.81 |
| Ex-US (EU + UK + Japan via SAD) commercial NPV | $250M peak sales × 3.5x × 65% probability-weighted / 254M shares | +2.24 |
| Net cash per share (post Q3 burn) | ($174M Q2 cash − $30M debt − $35M est. Q3 burn) / 254M shares | +0.43 |
| Non-dilutive capital on approval (loan tranches) | $150M × 75% prob × 50% capitalized value / 254M shares | +0.22 |
| Rejection scenario residual value (if denied) | 25% × $0.60 (cash-only floor after extended burn) / 1 share | +0.15 |
| Class action litigation reserve | Est. $20M settlement range × 70% prob / 254M shares (negative) | −0.05 |
| Pipeline optionality (molgramostim in NTM, hPAP) | Early signal only, 10% prob × $100M NPV / 254M shares | +0.04 |
| Dilution risk (potential pre-launch raise if rejected) | 15% prob × 20% dilution impact ≈ (negative, bear-case only) | −0.09 |
| FV base case | Arithmetic sum of components above | ≈ $8.75 |
Insider transactions (last 12 months): Bain Capital Life Sciences (institutional holder) added SVRA position in Sept 2025 (Form 4). No material insider selling >$500K at CFO/CEO level in last 12 months (insider ownership structurally low at 2.1% — mostly diluted by institutional raises). Short interest at 17% is interpreted as elevated binary bet against FDA approval; a positive PDUFA outcome could trigger short covering with upside amplification.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance 2027 |
|---|---|---|---|---|---|
| Revenue ($M) | 0.0 | 0.0 | 0.0 | 0.0 | 30–50 (launch) |
| R&D expense ($M) | −72.4 | −78.2 | −88.5 | ~−90 | −80 |
| SG&A expense ($M) | −24.1 | −32.6 | −52.3 | ~−80 | −100 (commercial) |
| Net loss ($M) | −93.4 | −108.2 | −135.8 | ~−160 | −140 (launch yr) |
| Cash & ST inv. ($M) | 82.6 | 215.4 | 218.7 | ~140 | ~250 (+approval tranches) |
| LT debt ($M) | 0.0 | 0.0 | 30.1 | 30.1 | up to 150 (non-dilutive) |
| Shares outstanding (M) | 167.3 | 192.5 | 205.0 | 254.1 | ~260 (minor) |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| R&D ($M) | 20.1 | 20.6 | 23.4 | 23.4 | 22.0 |
| SG&A ($M) | 8.4 | 9.6 | 13.1 | 15.6 | 19.0 |
| Net loss ($M) | −25.8 | −29.6 | −35.9 | −37.3 | −40.2 |
| End-of-period cash ($M) | 235.0 | 205.3 | 218.7 | 206.5 | 173.0 |
Business model — First-in-class inhaled therapy for orphan lung disease
MOLBREEVI — US (aPAP) ~$300–500M peak sales FY2029–2031E 🟢 PDUFA Nov 22, 2026 Priority Review, Fast Track, Orphan Drug Designation. ~8,300 prevalent US patients. Target 25–40% peak penetration. First-mover advantage: no approved US therapy. Fujifilm partner handles BLA-grade manufacturing. MOLBREEVI — Ex-US (EU, UK, JP) ~$150–300M peak sales FY2030–2032E 🟡 EMA Q1 2027 / UK pending EMA MAA validated; UK MHRA accepted. Japan via Nobelpharma partnership (SAD approved as SARGMALIN in 2024). EU accounts for ~40% of 7MM aPAP market by patients. Pipeline optionality Early-stage — not yet modeled 🟡 pre-clinical Molgramostim exploration in hereditary PAP (hPAP) and non-tuberculous mycobacterial (NTM) infections — early signal only. Low probability contribution to current FV.
Legal, regulatory and risk analysis
SWOT analysis
- +Phase 3 IMPALA-2 statistically significant on primary + secondary endpoints
- +First-in-class potential: no US-approved therapy for aPAP
- +Orphan + Priority Review + Fast Track designations
- +Fujifilm BLA-grade manufacturing agreement resolves prior CMC gap
- +$174M cash + $150M non-dilutive loan on approval = ~$320M post-approval liquidity
- −Pre-revenue; annual burn $130–160M; cash runway limited absent approval
- −Single-asset company — no diversification against regulatory risk
- −24% share dilution over last 12 months; insider ownership only 2.1%
- −Class action securities fraud lawsuits ongoing; potential $15–30M settlement
- →PDUFA Nov 22, 2026 approval triggers immediate commercial launch
- →EMA MAA in Q1 2027 — EU peak sales potential $150–250M
- →Orphan pricing ($150–200K/patient) + 7-year US market exclusivity
- →17% short interest fuels potential squeeze on positive catalyst
- →Strategic optionality: acquisition target for mid-cap specialty pharma post-approval
- !Second CRL (CMC or label) → stock drops 40–50% to residual floor
- !Launch disappointment: slow uptake, payer pushback, limited HCP network
- !Competitive entry: Nobelpharma's SARGMALIN in Japan; next-gen biologics in development
- !Macro biotech sell-off; XBI vulnerability on rate/sentiment shocks
Summary by assessment area
- Cash $174M covers burn through PDUFA + ~6 months post-approval buffer
- $150M non-dilutive loan on approval mitigates dilution scenario
- If rejected: raise needed in 2027, likely 15–20% dilution
- PDUFA Nov 22, 2026 — the single determinant of thesis
- EMA decision Q1 2027; UK MHRA Q2 2027
- Commercial launch Q1 2027 (first ever revenue line)
- Class action securities fraud lawsuits active (Pomerantz, Schall, et al.)
- Class period 2024-03-07 to 2025-05-23; lead plaintiff deadline passed
- Estimated settlement $15–30M (modeled as negative FV adjustment)
Sources: Savara Q2 2026 10-Q, FDA review extension announcement (Aug 2026), IMPALA-2 Phase 3 publications (ATS 2026), Simply Wall St, StockAnalysis.com, Stocktitan, TipRanks, Pomerantz/Schall class action filings, DelveInsight aPAP market report, consensus analyst targets (LifeSci Capital $11, Citizens JMP $11, Guggenheim $8, Oppenheimer $6, consensus avg $9.36 as of Sep 8, 2026). Market data — last verified close 2026-10-05: SVRA ~$4.79, market cap ~$1.22B, 52W: $3.34–$7.01, 254.14M shares outstanding. Short interest: 17.06%. EV: $1.08B. Cash + ST investments: $174M (Q2 2026). Insider ownership: 2.1%. Institutional ownership: 58.1%. Avg daily volume: 2.1M shares. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.